Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| FTLF | PRESS-RELEASE | neutral | 2/10 | FitLife Brands announced it will report Q1 2026 financial results on May 14, 2026. No preliminary financial data or guid | May 5, 2026 |
| SCLX | PRESS-RELEASE | bullish | 8/10 | Scilex's indirect subsidiary, ACEA Therapeutics, has agreed to sell ACEA Pharma to Phoenix Asia Holdings in exchange for | May 5, 2026 |
| OCGN | PRESS-RELEASE | mixed | 6/10 | Ocugen reported Q1 2026 EPS of -$0.06, a 16.1% miss vs consensus of -$0.05, with revenue of $1.53M (in line). The miss w | May 5, 2026 |
| IRON | PRESS-RELEASE | neutral | 5/10 | Disc Medicine reported Q1 2026 EPS of -$1.65, slightly beating the -$1.73 consensus by 4.6%, but net loss widened to $63 | May 5, 2026 |
| OCGN | PRESS-RELEASE | bearish | 7/10 | Ocugen priced $115M of 6.75% convertible senior notes due 2034 at a 90% discount to par, with net proceeds of ~$99.5M ($ | May 5, 2026 |
| CYTK | PRESS-RELEASE | bullish | 8/10 | Cytokinetics announced positive topline results from the ACACIA-HCM Phase 3 trial of aficamten in non-obstructive HCM, m | May 5, 2026 |
| BBIO | PRESS-RELEASE | neutral | 3/10 | BridgeBio Pharma announced it will present additional Phase 3 data for encaleret in ADH1 at the 2026 European Congress o | May 5, 2026 |
| CLRB | PRESS-RELEASE | bullish | 8/10 | Cellectar Biosciences announced updated 12-month follow-up data from its Phase 2b CLOVER WaM trial of iopofosine I 131 i | May 5, 2026 |
| RYTM | PRESS-RELEASE | bullish | 7/10 | Rhythm Pharmaceuticals reported Q1 2026 revenue of $60.1M, beating the $56.1M consensus, and an EPS loss of -$0.73, beat | May 5, 2026 |
| OCUL | PRESS-RELEASE | mixed | 6/10 | Ocular Therapeutix reported Q1 2026 EPS of -$0.29, beating consensus of -$0.32 by 9.4%, while revenue of $10.8M was belo | May 5, 2026 |
| MCRB | PRESS-RELEASE | bearish | 6/10 | Seres Therapeutics reported a Q1 2026 net loss of $19.9 million versus net income of $32.7 million in Q1 2025, which inc | May 5, 2026 |
| EDIT | PRESS-RELEASE | bearish | 6/10 | Editas Medicine reported Q1 2026 EPS of -$0.26, slightly worse than the -$0.24 consensus (a miss), while revenue of $2.8 | May 5, 2026 |
| ARVN | PRESS-RELEASE | neutral | 1/10 | Arvinas Inc. announced it will report its Q1 2026 results on May 12, 2026. | May 5, 2026 |
| RGEN | PRESS-RELEASE | bullish | 7/10 | Repligen reported Q1 2026 adjusted EPS of $0.48, beating the $0.38 consensus by 26.3%, and revenue of $194M (+15% YoY, + | May 5, 2026 |
| QURE | PRESS-RELEASE | bearish | 6/10 | uniQure reported Q1 2026 EPS of -$0.85, missing the consensus estimate of -$0.75 by 13.3%, and revenue of $3.6M, below t | May 5, 2026 |
| BNTX | PRESS-RELEASE | mixed | 6/10 | BioNTech reported Q1 2026 revenue of €118.1M (down 35% YoY) and a GAAP net loss of €531.9M (diluted EPS -€2.10), which b | May 5, 2026 |
| OCS | PRESS-RELEASE | neutral | 5/10 | Oculis presented DME AWARE Delphi study results at ARVO 2026, reinforcing unmet need for non-invasive early DME treatmen | May 5, 2026 |
| NBTX | PRESS-RELEASE | neutral | 5/10 | Nanobiotix announced FDA acceptance of a protocol amendment to its pivotal NANORAY-312 study for JNJ-1900 (NBTXR3) in he | May 4, 2026 |
| TLX | PRESS-RELEASE | bullish | 5/10 | Telix announced publication of exploratory Phase 3 ZIRCON data in European Urology showing TLX250-Px PET/CT is highly pr | May 4, 2026 |
| ANAB | PRESS-RELEASE | bullish | 7/10 | AnaptysBio reported Q4 2025 EPS of $1.58, a 268% beat vs consensus of -$0.94, indicating strong operational performance. | May 4, 2026 |
| PRAX | PRESS-RELEASE | neutral | 1/10 | Praxis Precision Medicines, Inc. announced it will report its Q1 2026 results on May 7, 2026. | May 4, 2026 |
| FBLG | PRESS-RELEASE | neutral | 3/10 | FibroBiologics announced preclinical results suggesting that its human dermal fibroblast spheroid treatment may reduce i | May 4, 2026 |
| CYTK | PRESS-RELEASE | neutral | 3/10 | Cytokinetics announced it will report topline results from its ACACIA-HCM trial (aficamten in non-obstructive HCM) on Ma | May 4, 2026 |
| CHRS | PRESS-RELEASE | neutral | 1/10 | Coherus Oncology, Inc. announced it will report its Q1 2026 results on May 11, 2026. | May 4, 2026 |
| AURA | PRESS-RELEASE | bearish | 7/10 | Aura Biosciences priced a large underwritten public offering of ~43.4M shares/pre-funded warrants at $6.00, expecting gr | May 4, 2026 |
| GYRE | PRESS-RELEASE | bullish | 7/10 | Gyre Therapeutics closed its all-stock acquisition of Cullgen Inc. for approximately $300 million, gaining a commercial- | May 4, 2026 |
| LQDA | PRESS-RELEASE | neutral | 1/10 | Liquidia Technologies, Inc. announced it will report its Q1 2026 results on May 11, 2026. | May 4, 2026 |
| FBIO | PRESS-RELEASE | neutral | 2/10 | Fortress Biotech announced CEO participation in a fireside chat at the H.C. Wainwright Royalty Conference. No financial | May 4, 2026 |
| BCAX | PRESS-RELEASE | neutral | 1/10 | Bicara Therapeutics Inc. announced it will report its Q1 2026 results on May 11, 2026. | May 4, 2026 |
| FBLG | PRESS-RELEASE | neutral | 4/10 | FibroBiologics announced the release of the first cGMP batch of its CYWC628 drug product for a Phase 1/2 clinical trial | May 4, 2026 |